Currently, MUM1 itself is not a direct target for therapy. However, understanding its role in the pathogenesis of certain lymphomas can help guide treatment strategies. For instance, it can inform the use of targeted therapies that disrupt the signaling pathways involved in B-cell activation and proliferation. Ongoing research is exploring how modulating MUM1 expression or function can impact cancer treatment outcomes.
